Lung Cancers Today
Advertisement
The registry, launched by the Florez Lab in 2023, is collecting data from around the world.
Indoor air pollutants can come from multiple sources and can be risk factors for developing lung cancer.
The 5-year scoping review provided insights on the different abstracts and educational content presented at 12 meetings.
Officials plan to submit a supplemental New Drug Application for the use of the combination therapy in this setting.
The FDA approved Optune Lua, a wearable TTFields treatment, for concurrent use with PD-1/PD-L1 inhibitors or docetaxel.
Shirish M. Gadgeel, MD, shares how treatment options and patient outcomes have evolved since he began practicing.
Researchers conducted an analysis of CheckMate 227 and CheckMate 9LA studies to evaluate pooled patient outcomes.
Dr. Gieske shares what the White Ribbon Project means to him as a lung cancer clinician.
Gene Ho, MPH, discusses real-world data on adverse events and survival outcomes with immunotherapy for NSCLC.
Researchers presented results from the randomized controlled trial of mPATH-Lung at the CHEST Annual Meeting.
Jamie L. Studts, PhD, discusses the use of the QUILS™ system in Kentucky and the importance of community engagement.
Annette McWilliams, MBBS, FRACP, PhD, discusses her IASLC Presidential Symposium presentation on the study.
Jill Feldman, a patient advocate, discusses how the lexicon can improve communication and empower patients.
The CheckMate 77T trial evaluated the efficacy of adjuvant and neoadjuvant nivolumab in resectable, untreated NSCLC.
Robert E. Merritt, MD, MBA, FACS, discusses the analysis he presented at the IASLC 2024 World Conference on Lung Cancer.
Shirish M. Gadgeel, MD, discusses the phase 1/2 ARROS-1 and ALKOVE-1 studies presented at the ESMO 2024 Congress.
The results of the phase 3 NRG Oncology/Alliance LU005 trial were presented during the 2024 ASTRO Annual Meeting.
The real-world study was presented at the IASLC 2024 World Conference on Lung Cancer.
The approval is based on results from the phase 3 LAURA trial.
Dr. Rolfo discusses results of an analysis that evaluated the impact of BMI on TTFields therapy.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.